Neuro®bromatosis 2 (NF2) is an inherited disorder characterized by a predisposition to multiple intracranial tumors. The protein encoded by the NF2 gene has striking similarities to ezrin, radixin and moesin (ERM) proteins which link membrane proteins to the cytoskeleton. Therefore, it can be speculated that the disruption of cytoskeletal organization by alterations in the NF2 gene is involved in the development of tumors. It has been reported that the majority of NF2 mutations were nonsense or frameshift mutations that result in premature termination of translation. To facilitate the detection of these mutations, we performed protein truncation test and found that 11 of 14 NF2 patients had truncational mutations (79%). Seven of the 11 patients (64%) had a splicing abnormality which lead to absence of exons in the ERM homology domain. To examine the biological signi®cance of the exon-missing mutations in the ERM homology domain, we expressed the wild-type (wt-NF2) and the various mutant NF2s (mu-NF2s) in a ®broblast cell line by using both liposome-mediated transfection and nuclear microinjection of the expression plasmids. The wt-NF2 showed intense punctate staining in the perinuclear cytoplasm in addition to overall staining of the submembranous area, whereas the mu-NF2s lacking exons in the ERM homology domain showed granular staining at the perinuclear region without any accumulation at the submembrane region. Microinjection of wt-NF2 cDNA into the nucleus of VA13 cells revealed that wt-NF2 protein induced a progressive elongation of cell processes. Furthermore, cells that expressed mu-NF2 had decreased adhesion, which resulted in detachment from the substratum. These ®ndings suggested that the exonmissing mutations in the ERM-homology domain may aect cell membrane ± cytoskeleton signaling and consequently disrupt cell ± to ± cell or cell ± to ± matrix interaction.
Introduction
Neuro®bromatosis type 2 (NF2) is an autosomaldominantly inherited disorder aecting approximately 1/40 000 individuals, and it is characterized by the development of multiple intracranial tumors (Evans et al., 1992) . NF2 patients frequently suer from bilateral vestibular schwannomas and meningiomas and occasionally from ependymomas, gliomas, and neuro®bromas (Martuza and Eldridge, 1988) . The NF2 gene was identi®ed on the long arm of chromosome 22q12 and found to encode a 595 amino acid protein which is called merlin or schwannomin (Rouleau et al., 1993; Trofatter et al., 1993) . The amino (N)-terminal half of merlin has a striking similarity to the ezrin-radixin-moesin (ERM) family proteins which play a role in linking the cell membrane and the cytoskeleton (Tsukita and Yonemura, 1997) .
Mutations of the NF2 gene have been found in not only germline DNA of NF2 patients but also in DNA derived from some sporadic intracranial tumors of non-NF2 patients (Arakawa et al., 1994; Jacoby et al., 1994; Rubio et al., 1994; Bianchi et al., 1995; De Vitis et al., 1996) . The majority of the NF2 mutations were nonsense or frameshift mutations that resulted in premature termination of translation Welling et al., 1996) . About 70% of the mutations were shown to cluster in the region encoding the N-terminal half of merlin. We previously showed that merlin bound to ®ve cellular proteins (p165, p145, p125, p85 and p70), which we named merlin-binding proteins (MBPs) , and that the N-terminal 339 amino-acids of merlin were essential for interacting with the MBPs (Takeshima et al., 1994; Nishi et al., 1997) . Therefore, most of the NF2 mutations which frequently occur in the ERMhomology domain of merlin generate an altered or truncated merlin which can not form a protein complex with MBPs. These ®ndings allowed us to hypothesize that the mutations impaired binding of MBPs with merlin to disrupt cell membrane-cytoskeleton signaling and consequently cause intracranial tumors in NF2 and non-NF2 patients. To prove this hypothesis, dierences between wild-type (wt-) and mutant (mu) NF2 in subcellular localization and diering biological responses of cells expressing wtand mu-NF2s need to be investigated.
In this study, we ®rst utilized a protein truncation test (PTT), which allowed rapid and sensitive detection of translation-terminating mutations, to screen for NF2 mutations. The PTT analysis demonstrated that about 80% of NF2 patients have translation-terminating mutations in the NF2 gene and that a majority of the premature terminations were caused by absence of exon(s) in the MBPs-binding region of the NF2 transcript. Furthermore, we constructed mammalian expression plasmids containing wt-and various exonmissing mu-NF2 cDNAs obtained from the NF2-related tumor samples, examined the subcellular localization of each expressed protein, and compared biological responses of the wt-with the exon-missing mu-NF2 expressing cells.
Our ®ndings demonstrated that merlin may play an important role in processes of cell ± to ± cell or cell ± to ± matrix adhesion and elongation of the cytoplasmic protrusion. Alterations due to the absence of an exon in the ERM-homology domain, which corresponds to the MBPs binding domain, caused a change in subcellular localization of the protein and in cell adhesion signaling.
Results

Mutational analysis of the NF2 gene in tumors from NF2 patients by PTT assay
We examined mutations of the NF2 gene in 14 tumors of clinically diagnosed NF2 patients by PTT. A 1.8 kb fragment of NF2 cDNA, encompassing a full-length open reading frame (ORF), was ampli®ed from mRNA extracted from the tumor tissues and subjected to PTT. All of the normal control samples tested showed a predominant 75 kDa translation product corresponding to the size of the wt-merlin. To con®rm the ®nding obtained by the full-length This sample was found to have two abnormal transcripts, one had a nonsense mutation at codon 481 and the other displayed an absence of exon 2 in addition to the nonsense mutation at codon 481. of NF2 mutations by full-length (a) and segmental protein truncation tests (PTT) (b, N-terminal half; c, Cterminal half). Truncated NF2 proteins were detected in tumor samples from representative patients with NF2. Novel bands, corresponding to the truncated proteins, are indicated by asterisks. Case 2 showed an aberrantly migrating band in the N-terminal half but not in the full-length. Cases 1, 3, 4, 7, 8, 11 and 13 predominantly showed aberrantly migrating bands, ®ndings which were thought to indicate the lack of or reduction of wild-type allele expression NF2 PTT assay, we also examined the N-terminal half (codons 1 ± 294) and the C-terminal half (codons 255 ± 595) of the NF2 gene by the PTT assay.
A total of 11 aberrantly migrating bands were detected in the 14 tumor samples by the full-length and the segmental PTT assays (Figure 1 , Table 1 ). Interestingly, seven of the 11 tumor samples which exhibited aberrantly migrating bands in the PTT assay showed a reduction in the intensity of a band corresponding to the wt-merlin (sample numbers: 1, 3, 8, 13 in Figure 1a ; sample numbers: 4, 7, 11 in Figure 1b ). This ®nding suggested that these tumor cells were devoid of a wt-NF2 allele or suppressed mRNA expression transcribed from the wt-NF2 allele. Lysates were prepared from VA13 cells which had been transfected with several types of pCGN-NF2. The NF2 proteins expressed were detected by anti-HA antibody (b-upper, c, d-upper and e) , anti-NF2 polyclonal antibody (b-lower) and anti-NF2-C terminal rabbit polyclonal antibody C18 (Santa Cruz Biotechnology). Next, 0.5% Triton X-100 soluble and insoluble fractions were prepared and an equal amount of lysate was separated by 10% (b) or 15% (c) SDS ± PAGE. Transfected cells were divided into adherent and detached cell fractions and lysed by 2% SDS containing sample buer. The same amount of lysate was separated on 10% (d) or 10 ± 20% gradient (e) SDS ± PAGE Subsequently, a DNA sequence analysis of the ampli®ed NF2 cDNA from the tumor mRNA was performed in the 11 PTT-positive samples. All samples were observed to have sequence alterations in the NF2 gene, as summarized in Table 1 . Three samples, 3, 5 and 9, were found to have a nonsense mutation at codons 341, 481 and 144, respectively. Sample 2 was shown to exhibit a 4-bp deletion beginning at the second position of codon 242. This deletion produced a frameshift with a new stop codon located 23 nts downstream. The other seven samples, 1, 4, 7, 8, 10, 11 and 13, had an abnormal transcript that lacked the exons speci®ed in Table 1 . The absence of exon 2 and/ or exon 3 generated an in-frame deletion, whereas loss of exon 6, exon 7 or exon 15 caused a frameshift which resulted in premature termination of protein synthesis. It was noteworthy that sample 5 was found to have two abnormal transcripts: one had a nonsense mutation at codon 481 and the other displayed an absence of exon 2 in addition to a nonsense mutation at codon 481.
Subcellular localization of wt-and mu-NF2 proteins
To identify biological dierences between the wt-and mu-NF2s, we investigated the subcellular localization of these proteins. Based on the results obtained by the PTT and DNA sequence analyses, we constructed an HA-tagged wt-NF2 and four HA-tagged mu-NF2 expression plasmids as illustrated in Figure 2a . NF2-480 is a C-terminal deletion mutant which lacked amino acids 481 ± 595; 438DE2 is an exon 2-missing mutant which had an internal deletion between amino acids 39 ± 80 with C-terminal deletion 481 ± 595; 173DE6 and 224DE7 expressed truncated proteins which are generated by the absence of exons 6 and 7, respectively. NF2-480 retains the entire N-terminal ERM-homology domain; 438DE2, 173DE6 and 224DE7 exhibit a partial deletion or truncation of the ERM-homology domain. To eliminate the in¯uence of endogenous merlin, the SV40-transformed fetal lung ®bloblast cell line VA13, in which endogenous merlin was scarcely detected by a speci®c antibody, was used for the transfection experiments.
First, a Western blot analysis of VA13 cells transfected with wt-and mu-NF2 expression plasmids was performed using anti-HA antibody. As shown in Figure 2b and c, wild-type and NF2-480 were dominantly detected in the 0.5% Triton-X 100 soluble fraction, whereas 438DE2, 173DE6 and 224DE7 were identi®ed in the 0.5% Triton-X 100 insoluble fraction. The Western blot analysis revealed that 438DE2, 173DE6 and 224DE7 were highly expressed in the detached cells compared to the adherent cells, whereas NF2-480 was exclusively detected in the adherent cells and not in the detached cells (Figure 2d and e). The wt-merlin was detected in both adherent and detached cells. These ®ndings indicated that cells expressing the mu-merlin, which has an alteration in the ERM-homology domain, 438DE2, 173DE6 and 224DE7, lose the ability to attach to the culture plate.
For identi®cation of the subcellular localization of wt-and mu-NF2, a confocal laser scanning microscope (CLSM) analysis of the VA13 cells transfected with wt-and mu-NF2 expression plasmids was performed. Wt-NF2 was observed diusely in the cytoplasm in addition to overall staining of the membrane. Intense punctate staining of the protein was also observed in perinuclear and peripheral cytoplasm even in extended cell processes. In addition, some cells showed marked morphological changes and became spherical with very long cell processes, more than 100 mm in length (Figure 3a ± c). The NF2-480 protein, lacking the C-terminal portion of merlin, was diusely expressed in cytoplasm and cell processes without any of the punctate staining which was found in wt-NF2 (Figure 3d and e). NF2-438DE2 protein was observed diusely in the cytoplasm, and most of the cells expressing NF2- Figure 3 Subcellular localization of the wild-type and mu-NF2 proteins in transfected VA13 cells. NF2 proteins expressed by the transfection of HA-tagged NF2 plasmids were detected by anti-HA antibody followed by FITC-conjugated secondary antibody (green¯uorescence). Nuclei were stained by propidium iodide (red¯uorescence). (a, b and d) are¯uorescence micrographs, (c and e) are Nomarski views, and (f) is a combined phase contrast-¯uorescence micrograph. a ± c show transfectants of pCGN-NF2-Full, d and e show those of pCGN-NF2-480, and f shows those of pCGN-NF2-438DE2. Arrows indicate the elongated cell process (b and c) and peripheral margin of the cell (e). All photographs were taken at the same magni®cation (4006) 438DE2 became spherical and tended to detach from the substratum 48 h after transfection (Figure 3f ). Cells transfected with 173DE6 or 224DE7 also showed a perturbation of cell adhesion, and were therefore scarce on the culture plate 48 h after transfection. In contrast, cells expressing NF2-480 tightly attached on the plate even 72 h after the transfection.
These ®ndings were not speci®c to VA13 cells; similar results were obtained with COS-7 cells (data not shown). To test the possibility that cell detachment caused by the expression of the 438DE2, 173DE6 and 224DE7 mutants was the result of cell death, we examined the viability of detached cells by double staining of Calcein-AM and propidium iodide. More than 80% of the detached cells did not show apoptotic changes. Moreover, a Western blot analysis revealed that the three mutants (438DE2, 173DE6 and 224DE7) were accumulated in detached cells for up to 120 h without degradation (data not shown).
Temporal changes in the subcellular localization of wtand mu-NF2s
To investigate changes with time in the subcellular localization of wt-and mu-NF2s and the morphological changes of the cells, we performed a CLSM analysis of VA13 cells in which the expression plasmid encoding wt-or various mu-NF2s was microinjected in the nuclei. At 3 h after microinjection, expression of wt-NF2 was observed as ®ne granular staining spread diusely throughout the cytoplasm. There was particularly abundant expression of wt-NF2 in cell Figure 4 Temporal observation of the wt-NF2 expressing VA13 cells. pCGN-NF2-Full was microinjected into the nucleus of VA13 cells, and then the cells were ®xed and double-stained by anti-HA antibody followed by FITC-conjugated secondary antibody (green uorescence) and rhodamine-conjugated phalloidin (red¯uorescence) at appropriate times after microinjection. Digital images were captured from two dierent channels, and a ± c each show the FITC channel on the left side, a composite image in the center, and the rhodamine channel on the right side. The nuclear staining observed in the rhodamine channel at 3 ± 6 h after microinjection was due to the Dextrane Texas Red, which was comicroinjected as a marker. The images in a ± c were obtained at 3, 6 and 12 h after microinjection, respectively. Note that full-length NF2 and polymerized actin were colocalized at the cell periphery and the extended cell process (indicated by arrow), but not actin with stress ®bers in the cytoplasm processes that attached to adjacent cells (Figure 4a) . At 6 h after the injection, the cells began to show discrete local punctate staining with outgrowths of the cell processes (Figure 4b ). Twelve to twenty-four hours after injection, the con®guration of the cell bodies changed from epithelial to rounded, with many long and thin protrusions (Figure 4c) .
The NF2-480-expressing cells at 3 h after microinjection showed a morphology and subcellular distribution of the expressed protein similar to the wt-NF2-expressing cells (Figure 5a ). This ®nding did not change throughout the observation period (3 ± 24 h). Rhodamine-conjugated phalloidin staining revealed that the NF2-480 was colocalized with polymerized actin at the ruing membrane but not with stress ®bers. In contrast, the NF2-438DE2 protein accumulated in the nucleus and perinuclear region but was not found at the cell membrane at 3 h after microinjection (Figure 5b) . At 6 h after injection, granular staining was found at the perinuclear region, and nuclear staining was reduced (Figure 5c ). This aggregation of the mu-NF2 was not seen in the contour of the cells, and persisted until 12 h after microinjection (Figure 5d ). Twenty-four hours after injection, the cells expressing NF2-438DE2 became spherical and began to¯oat o the substratum. Subcellular localization of NF2-553DE2 protein, which has an intact C-terminus missing exon 2, was similar to that of NF2-438DE2. The NF2-553DE2 protein accumulated in the nucleus at 3 h ( Figure 5e ) and translocated to the perinuclear region at 12 h after injection (Figure 5f ). The cells expressing NF2-553DE2 also detached from the substratum by 24 h after injection. These ®ndings suggested that the MBPs-binding domain mutation had a greater impact on subcellular localization of the expressed protein and cellular phenotype than did the lack of C-terminal domain. Although the mutant merlin NF2-224DE7 revealed a subcellular localization similar to that of NF2-438DE2, NF2-224DE7 showed more rapid changes. The perinuclear granule of the protein was observed at 3 h and nuclear staining completely disappeared at 6 h ( Figure 6 ). The NF2-224DE7 plasmid-injected cells were completely detached by 24 h. These ®ndings were consistent with the results of the Western blotting and CLSM analyses of the cationic lipid reagent-mediated transfection.
To examine whether cell detachment was caused by a dominant eect of the mu-NF2 which had an alteration in the ERM-homology domain, we performed nuclear microinjection of both wt-NF2 cDNA fused with the green¯uorescent protein (GFP) gene (pEGFP-NF2-Full) and HA epitope-tagged 224DE7 cDNA into VA13 cells. As shown in Figure 7 , the cells expressing both wt-NF2 and 224DE7 became spherical and began to detach from the substratum at 12 h after injection. This ®nding strongly suggested that ERM-homology domain mutants have dominant eect on cell detachment.
Discussion
In this study, we analysed 14 tumor samples from clinically diagnosed NF2 patients by PTT. Truncated merlin were detected in 11 of the 14 samples. DNA sequence analysis of 11 PTT-positive samples revealed that two had a nonsense mutation, one had a 4-bp deletion, seven had splicing abnormalities resulting in the absence of certain exons, and one had a nonsense mutation with absence of exon 2 by splicing abnormality. Nine of the 11 PTT-positive patients had alterations in the N-terminal half of merlin, which corresponded to the MBPs binding domain. The other two patients (cases #3 and #8) who showed later onset (54 y.o. and 63 y.o.) had a nonsense mutation and the absence of an exon in the C-terminal half of merlin, respectively. These ®ndings implied that the preservation of the MBPs binding domain may be associated with a later onset of clinical symptoms.
The PTT approach has been widely used for the mutation analysis of various tumor suppressor genes such as APC and hMLH1 which exhibit large stretches of coding regions with mutation spectra characterized by a preponderance of translationterminating mutations (Powell et al., 1993; Papadopoulos et al., 1994 ; van der Luijt et al., 1994; Bala et , 1996) . In this study, we frequently detected splicing abnormalities which lead to the absence of exons in tumor samples from NF2 patients. This study therefore detected a much higher incidence of NF2 alterations in NF2 patients than the previously reported mutational analyses performed by SSCP and DGGE methods Welling et al., 1996) . We previously reported that the absence of exon 2 resulted in the loss of the ability of merlin to interact with MBPs (Takeshima et al., 1994; Nishi et al., 1997) , but the functional signi®cance of the exon skipping has not yet been clari®ed. Therefore, we compared the subcellular localization and biological aspects of four types of exon-missing mutants with the wild-type merlin in the present study. The transfected wild-type merlin showed intense punctate staining in the perinuclear cytoplasm in addition to overall staining of the submembranous area. Several investigators have reported the subcellular localization of wild-type merlin; den Bakker et al. (1995a,b) revealed that transfected wild-type merlin localized on the ventral cell membrane of COS cells with the punctate staining pattern, which was similar to our observation. Figure 6 Temporal observation of the NF2-224DE7 expressing VA13 cells. (a and b) indicate 3 and 6 h after microinjection of pCGN-NF2-224DE7, respectively. Each panel shows the FITC channel on the left side, a composite image in the center, and the rhodamine channel on the right side. Note that the aggregation dots are observed even at 3 h and nuclear staining has completely disappeared at 6 h Figure 7 Temporal observation of the co-expressed wt-and mu-NF2 in VA13 cells. pEGFP-NF2-Full and pCGN-NF2-224DE7 were co-microinjected into the nucleus of VA13 cells, and then the cells were ®xed and stained by anti-HA antibody followed by Cy3-conjugated secondary antibody (red¯uorescence). GFP-NF2-Full fusion protein was revealed by direct¯uorescence (green uorescence) at appropriate times after microinjection (a ± d; 6 h, e ± h; 12 h). Digital images were captured from two dierent channels (a and e, FITC channel; c and g, Cy3 channel) and overlayed (b, f). d and h are Nomarski views. The injected cell which is seen in the center of h changed shape from epithelial to round and reduced cell attachment from the substatum. a ± d are shown in the plane where the cells attached to the substratum and e ± h are shown at 10 mm above it Stemmer-Rachamimov et al. (1997) recently reported that endogenous merlin was also detected at the perinuclear region, ruing membranes and cell ± to ± substrate adhesion areas. Gonzalez-Agosti et al. (1996) and Scherer and Gutmann (1996) revealed that endogenous merlin presented with polymerized actin ®bers at the peripheral cytoplasm, such as the ruing membrane, but not with stress ®bers. These ®ndings, together with our observations, revealed that wild-type merlin is mainly distributed at two sites in cells: the membrane edge and the perinuclear region. Western blot analysis revealed that wild-type merlin was present in both the 0.5% Triton-X 100 insoluble and soluble fractions. Contrarily, the NF2-480 mutant, which lacked the C-terminal portion of merlin was expressed in cytoplasma and cell processes without perinuclear punctate staining and was mostly detected in the 0.5% Triton-X 100 soluble fractions. These data implied that the highly charged and hydrophilic region of the C-terminal portion of merlin is involved in formation of the detergent insoluble punctate aggregation in the perinuclear area.
The phenotypical changes induced by the various NF2 mutant expressions, which are summarized in Figure 8 , suggested the function of each domain in NF2 protein. The C-terminus-deleted mutant (NF2-480), as well as wild-type merlin, was enriched in membrane edges. This ®nding suggested that the Nterminus half is required for merlin to associate with some cell membrane proteins. In contrast, the mutant merlins which had an absence of exons in the MBPs binding domain temporarily existed in nucleus and translocated to the perinuclear region, but not localized at the submembrane region. All these mutants induced the loss of the adhesive property of the cells. Moreover, co-microinjection of wt-and mu-NF2 (224DE7) into VA13 cells also induced detachment of the cells. These ®ndings indicated that mutation of the MBPs binding domain caused a dominant negative eect on cell attachment regulated by the wt-merlin and consequently impaired cell ± to ± cell or cell ± to ± matrix contact.
The con®gurations of cells microinjected with wt-NF2 cDNA changed over time from epithelial to a round shape with long and thin protrusions, whereas none of the mutants induced this phenotype. Lutchman and Rouleau (1995) also showed that wild-type NF2-transfected NIH3T3 cells were round, globular and had long processes, which were reversed by exposure to antisense oligonucleotides. These lines of evidence suggested that the expression of wild-type merlin is heavily associated with morphological changes including the elongation of cell processes. Furthermore, we have recently analyzed the tumor suppressive activity of the wt-NF2 gene by the loxP gene conditional activation system using recombinant adenovirus producing Cre recombinase. Induction of wt-NF2 expression in VA13 cells by the Cre-loxP activation system dramatically reduced growth and colony formation activity (Koga et al., in preparation) .
Our present results demonstrated that the absence of exons caused by the abnormal splicing of the NF2 transcript altered the subcellular localization of the NF2 proteins and consequently induced phenotypical changes in the cells. Accordingly, abnormal mRNA splicing, which causes the absence of exons, may act as one of the important mechanisms for inactivating the NF2 gene.
Material and methods
Human tissue samples and RNA extraction
Samples were obtained from 14 unrelated patients diagnosed as having NF2 and from peripheral blood lymphocytes (PBL) of 10 normal volunteers. The tumor samples were immediately frozen at 7808C until RNA extraction. RNA was extracted from the tumor specimens with a Micro-®rst RNA extraction kit (Invitrogen) according to the manufacturer's instructions, and total RNA was extracted from the PBL by a modi®ed acid guanidium thiocyanate-phenol-chloroform extraction method (Siebert and Chenchik, 1993) .
cDNA synthesis and reverse transcriptase-polymerase chain reaction (RT ± PCR) First-strand cDNA was synthesized from mRNA with Moloney murine leukemia virus reverse transcriptase (GIBCO) by the oligo-dT primer for the full-length and N-terminal half of NF2 cDNA. For the C-terminal half, NF2-AS2 primer (5'-TCTACGCGGCCGCAGTTCAAGG-CAATTGCACATAA-3') was used as a substitute for the oligo-dT primer. RT ± PCR of the full-length and Nterminal half was carried out by the two-step PCR procedure using rTth DNA polymerase (Perkin Elmer) which has proofreading activity. The ®rst PCR was performed for 30 cycles using NF2-NST (5'-TGGCCCT-GAGGCCTGTGCAGCAA-3') as the sense primer, and NF2-AS2 and T7PAS2-NF2 (5'-CTGGAGAATCAGCTT-ATTAACACG-3') as the antisense primers, respectively. Each cycle consisted of denaturation at 958C for 1 min, annealing at 658C for 1 min and extension at 728C for 2 min. The ®rst PCR product was used as a template in the second run, where T7PS1-NF2 (5'-GGATCCTAATACGA-CTCACTATAGGGAGACCACCATGGGGCTCAGAGT-GCAGGCCGTGGGGCGCGA-3') (the T7 promoter sequence followed by an 8-base translation initiation signal indicated by the underline) and NF2-HA-AS (5'-GGGT-GGTACCTAGAGCTCTTCAAAGAAGG-3') (the KpnI site is indicated by the underline) were utilized as primers to amplify the full-length NF2, and T7PS1-NF2 and DPN1AS2-NF2 (5'-GCTTATTAACACGAAGCTATGA-GGAGTTAAA CTTG-3') (the genuine terminal codon is indicated by the underline) were utilized as primers to amplify the N-terminal half of NF2. The second PCR was performed for 35 cycles with the same conditions as described above. Ampli®cation of the C-terminal half of NF2 was performed for 40 cycles using T7PS3-NF2 (5'-GGATCCTAATACGACTCACTATAGGGAGACCA-CCATGGTCTC CT TCCCGTG GAATGAA -3') as the sense primer and NF2-HA-AS as the antisense primer, with PCR conditions the same as above except for the annealing temperature (608C). To avoid missing mutations at the primer sites, DPN1AS2-NF2 and T7PS3-NF2 were designed to overlap by about 100 bp.
Protein truncation test (PTT)
Five ml of the ampli®ed DNA was added to 5 ml of the RNA transcription mixture. The ®nal mixture contained 0.5 mM each of NTP, 10 mM DTT, 10 U of T7 RNA polymerase and 10 U of RNase inhibitor (Ambion). The samples were incubated at 378C for 1 h and then further incubated with 1 U of RNase-free DNase for 20 min. One ml of the transcriptional products was added to 9 ml of the translation mixture, which contained 100 mM potassium acetate, 500 mM magnesium acetate, 40% rabbit reticulocyte lysate and 9 mCi of [ 35 S] methionine (Amersham). The samples were incubated in this mixture at 308C for 90 min. The samples were then diluted in sodium dodecyle sulfate (SDS) sample buer (2% SDS, 10% glycerol, 0.1 M DTT, 120 mM Tris-HCl, pH 6.8, 0.02% BPB), boiled for 5 min and resolved by 12 or 15% SDS-polyacrylamide gel electrophoresis (SDS ± PAGE). The gels were dried and subjected to autoradiography.
Sequencing analysis
Tumor samples showing a mobility shift on the PTT assay were directly sequenced with a DyeDeoxyTM Terminal Cycle Sequencing kit (Perkin Elmer). In selected cases, the ampli®ed products were also cloned in TA cloning vector (Invitrogen), and the DNA obtained from several (at least ®ve) clones was sequenced using the same kit to avoid errors introduced during the PCR reaction.
Construction of the NF2 expression plasmids
The full-length and truncated NF2 cDNA were ampli®ed by PCR from the cDNA of normal PBL and tumor tissue samples, respectively, by the primer NF2-HA-Sense (5'-GCCCTCTAGAATGGCCGGGGCCATCGCTTCCC-GCATGAGCTTCAGCTCTCTCAAG-3') containing a XbaI site (underlined) and the primer NF2-HA-AS containing a KpnI site. The cycling reactions were performed in a 25 ml reaction volume for 40 cycles using rTth DNA polymerase. Each cycle consisted of denaturation at 958C for 1 min, annealing at 608C for 1 min and extension at 728C for 2 min. The PCR fragments were digested with XbaI and KpnI and then ligated into a pCGN expression vector. The mutations of the insert were con®rmed by DNA sequence analysis. C-terminal-deleted and exon 2-, 6-, and 7-missing pCGN-NF2 were named pCGN-NF2-480, 438DE2, 553DE2, 173DE6 and 224DE7 respectively. To express HA epitope-tagged NF2, the pCGN-NF2 was transfected into SV40-transformed human ®broblast (VA13) and COS-7 cells by the liposomemediated gene transfer method (Felgner et al., 1987) . The construct corresponding to wt-merlin-green¯uorescent protein (GFP) fusion protein was made by ligating the KpnI fragment containing a full-length wt-NF2 cDNA into the eukaryotic expression vector pEGFP-C1 (Clontech). This constract was named pEGFP-NF2-Full and used for the microinjection experiment.
Cell cultures and preparation of cell extracts VA13 cells and Cos-7 cells were cultured in a 1 : 1 mixture of Dulbecco's modi®ed Eagle's minimum essential medium (D-MEM) and Ham's F12 nutrient medium (DMEM/ F12)(GIBCO) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS)(Bio-Whittaker) in a humidi®ed CO 2 incubator. Forty-eight hours after transfection of the pCGN-NF2, suspended cells were collected and used as detached fractions. The cells on plates were lysed with lysis buer (50 mM Tris HC1, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 54 mg/ml aprotinin, 100 mg/ml PMSF, 10 mg/ml leupeptin and 10 mg/ml pepstatin) on ice for 30 min. After centrifugation at 14 000 r.p.m. for 15 min, the supernatants were used as the 0.5% Triton X-100 soluble fraction. The pellets were washed with lysis buer and used as the 0.5% Triton X-100 insoluble fraction.
Western blot analysis
For the Western blot analysis, each fraction was boiled in SDS sample buer, and samples containing equal amounts of cell lysates extracted from equal numbers of cells were resolved by 10 ± 20% SDS ± PAGE. After being blotted on a nitrocellulose ®lter, the ®lters were blocked with phosphate-buered saline (PBS) containing 10% skim milk for 1 h at room temperature and then incubated with 1 : 2500 diluted anti-HA antibody (12CA5) or 1 : 2000 diluted anti-NF2 polyclonal antibody (Takeshima et al., 1994) in PBS containing 0.03% Tween 20 for 1 h, and washed three times with PBS containing 0.3% Tween 20. The ®lters were then incubated with horseradish peroxidase-conjugated anti-mouse IgG for anti-HA and anti-rat IgG (Amersham) for anti-NF2 antibody for 40 min, and speci®c proteins were detected using an enhanced chemiluminescence system (Amersham).
Immuno¯uorescence procedure and confocal laser scanning microscopic analysis (CLSM) Cells were seeded on glass-bottom culture dishes (MatTek Corp.) 48 h after transfection, and incubated an additional 24 h at 378C, then washed two times with PBS and ®xed in 4% PFA for 10 min followed by 0.2% Triton X-100 for 5 min. After being washed with PBS, the cells were incubated with diluted anti-HA monoclonal antibody (1 : 100) in PBS containing 0.3% bovine serum albumin (BSA) for 90 min at room temperature. After being washed with PBS, the cells were incubated with diluted FITC-conjugated secondary antibody (1 : 100) (Biosource) for 60 min. For the ®nal 5 min, propidium iodide (Sigma) was added to make a ®nal concentration of 1 mg/ml for nuclear staining. For F-actin staining, rhodamine phalloidin (Molecular Probes, Inc) was used instead of propidium iodide at 1 U/ml for 30 min. After being washed with PBS, samples were mounted in 50% glycerol and visualized with a confocal microscope (TCS 4D, Leica, Nussloch, Germany) equipped with an argon gas laser and appropriate ®lter sets to allow the simultaneous recording of¯uorescein. Fluorescence micrographs were recorded using PL APO 406objec-tives and were sampled with 102461024 pixels and 8-bit resolution per color. For Nomarski views, FLUOVIEW (OLYMPUS) was also used under essentially the same conditions.
Microinjection
For the nuclear microinjection, VA13 cells were plated onto CELLocate (Eppendorf) 48 h prior to injection. Wildtype and mutant pCGN-NF2 were microinjected, along with a marker (Dextrane Texas Red, 2 mg/ml), into the nucleus of cells by Micromanipulator 5171 (Eppendorf). The cells were then incubated for appropriate times at 378C. Injected cells were ®xed and stained as described above and examined with the CLSM.
